Lb Pharmaceuticals (LBRX) Accumulated Depreciation (2024 - 2026)

Lb Pharmaceuticals has reported Accumulated Depreciation for 3 years, with the latest figure at $502000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Depreciation changed N/A year-over-year to $502000.0; the trailing twelve-month figure through Mar 2026 stood at $502000.0 (changed N/A YoY), and the FY2025 full-year result was $420000.0, up 315.84% from the prior year.
• Accumulated Depreciation for Q1 2026 stood at $502000.0, up from $420000.0 in the prior quarter.
• The five-year high for Accumulated Depreciation was $502000.0 in Q1 2026, with the low at $101000.0 in Q4 2024.
• Average Accumulated Depreciation over 3 years is $340000.0, with a median of $378500.0 recorded in 2025.
• Peak annual rise in Accumulated Depreciation reached 315.84% in 2025, while the deepest fall reached 315.84% in 2025.
• Tracing LBRX's Accumulated Depreciation over 3 years: stood at $101000.0 in 2024, then surged by 315.84% to $420000.0 in 2025, then advanced by 19.52% to $502000.0 in 2026.
• The last three Accumulated Depreciation figures came in at $502000.0 (Q1 2026), $420000.0 (Q4 2025), and $337000.0 (Q3 2025), per Business Quant data.

Peer Comparison